{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:16:31Z","timestamp":1758399391046,"version":"3.28.0"},"reference-count":29,"publisher":"Georg Thieme Verlag KG","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Perinatol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>\n            Objective\u2003This study aimed to examine whether vaginal progesterone is noninferior to 17-\u03b1 hydroxyprogesterone caproate (17OHP-C) in the prevention of recurrent preterm birth (PTB).<\/jats:p><jats:p>\n            Study Design\u2003This retrospective cohort study included singleton pregnancies among women with a history of spontaneous PTB who received prenatal care at a single tertiary center from 2011 to 2016. Pregnancies were excluded if progesterone was not initiated prior to 24 weeks or the fetus had a major congenital anomaly. The primary outcome was PTB &lt;37 weeks. A priori, noninferiority was to be established if the upper bound of the adjusted two-sided 90% confidence interval (CI) for the difference in PTB fell below 9%. Inverse probability of treatment weighting (IPTW) was used to carefully control for confounding associated with choice of treatment and PTB. Adjusted differences in PTB proportions were estimated via IPTW regression, with standard errors adjustment for multiple pregnancies per woman. Secondary outcomes included PTB &lt;34 and &lt;28 weeks, spontaneous PTB, neonatal intensive care unit admission, and gestational age at delivery.<\/jats:p><jats:p>\n            Results\u2003Among 858 pregnancies, 41% (n\u2009=\u2009353) received vaginal progesterone and 59% (n\u2009=\u2009505) were given 17OHP-C. Vaginal progesterone use was more common later in the study period, and among women who established prenatal care later, had prior PTBs at later gestational ages, and whose race\/ethnicity was neither non-Hispanic white nor non-Hispanic Black. Vaginal progesterone did not meet noninferiority criteria compared with 17-OHPC in examining PTB &lt;37 weeks, with an IPTW adjusted difference of 3.4% (90% CI: \u22123.5, 10.3). For secondary outcomes, IPTW adjusted differences between treatment groups were generally small and CIs were wide.<\/jats:p><jats:p>\n            Conclusion\u2003We could not conclude noninferiority of vaginal progesterone to 17OHP-C; however, women and providers may be willing to accept a larger difference (&gt;9%) when considering the cost and availability of vaginal progesterone versus 17OHP-C. A well-designed randomized trial is needed.<\/jats:p><jats:p>\n            Key Points\n          <\/jats:p>","DOI":"10.1055\/s-0041-1740010","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:22:12Z","timestamp":1639527732000},"page":"1695-1703","source":"Crossref","is-referenced-by-count":2,"title":["A Comparison of Vaginal and Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth"],"prefix":"10.1055","volume":"40","author":[{"given":"Heather A.","family":"Frey","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew M.","family":"Finneran","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erinn M.","family":"Hade","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, Ohio"},{"name":"Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University College of Medicine, Columbus, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Waickman","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney D.","family":"Lynch","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay D.","family":"Iams","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark B.","family":"Landon","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1097\/AOG.0000000000004479","article-title":"Prediction and prevention of preterm birth. Practice Bulletin No. 234. The American College of Obstetricians and Gynecologists","volume":"138","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"24","key":"ref2","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa035140","article-title":"Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate","volume":"348","author":"P J Meis","year":"2003","journal-title":"N Engl J Med"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1067\/mob.2003.41","article-title":"Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study","volume":"188","author":"E B da Fonseca","year":"2003","journal-title":"Am J Obstet Gynecol"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/1471-0528.15566","article-title":"Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis","volume":"126","author":"A Jarde","year":"2019","journal-title":"BJOG"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(21)00217-8","article-title":"Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials","volume":"397","author":"EPPPIC Group","year":"2021","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(16)00350-0","article-title":"Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial","volume":"387","author":"J E Norman","year":"2016","journal-title":"Lancet"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/uog.5158","article-title":"Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial","volume":"30","author":"J M O'Brien","year":"2007","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/aogs.12017","article-title":"Prevention of preterm birth: a randomized trial of vaginal compared with intramuscular progesterone","volume":"92","author":"M A Maher","year":"2013","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref9","first-page":"284","article-title":"Effectiveness of vaginal versus intramuscular progesterone for the prevention of preterm delivery","volume":"22","author":"R Wajid","year":"2016","journal-title":"Ann King Edward Med Univ"},{"issue":"06","key":"ref10","first-page":"1301","article-title":"Comparative study of vaginal versus intramuscular progesterone in the prevention of preterm delivery: a randomized controlled trial","volume":"7","author":"A S Bafghi","year":"2015","journal-title":"Electron Physician"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijgo.2016.01.010","article-title":"A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth","volume":"134","author":"A Elimian","year":"2016","journal-title":"Int J Gynaecol Obstet"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1080\/01443615.2018.1425380","article-title":"A randomised trial to compare 200\u2009mg micronised progesterone effervescent vaginal tablet daily with 250\u2009mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth","volume":"38","author":"S Shambhavi","year":"2018","journal-title":"J Obstet Gynaecol"},{"issue":"13","key":"ref13","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/1471-0528.16365","article-title":"Vaginal compared with intramuscular progestogen for preventing preterm birth in high-risk pregnant women (VICTORIA study): a multicentre, open-label randomised trial and meta-analysis","volume":"127","author":"S J Choi","year":"2020","journal-title":"BJOG"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/uog.17245","article-title":"Vaginal progesterone vs intramuscular 17\u03b1-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials","volume":"49","author":"G Saccone","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"B11","DOI":"10.1016\/j.ajog.2017.01.022","article-title":"The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth","volume":"216","author":"Society for Maternal-Fetal Medicine (SMFM) Publications Committee","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1097\/AOG.0000000000002308","article-title":"Progesterone for prevention of preterm birth: shortcomings and unintended consequences of the Orphan Drug Act","volume":"130","author":"R E Gee","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajog.2010.02.004","article-title":"Care for women with prior preterm birth","volume":"203","author":"J D Iams","year":"2010","journal-title":"Am J Obstet Gynecol"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.ajog.2007.09.016","article-title":"Second-trimester loss and subsequent pregnancy outcomes: What is the real risk?","volume":"197","author":"A G Edlow","year":"2007","journal-title":"Am J Obstet Gynecol"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12884-017-1393-6","article-title":"A multi-centre, non-inferiority, randomised controlled trial to compare a cervical pessary with a cervical cerclage in the prevention of preterm delivery in women with short cervical length and a history of preterm birth - PC study","volume":"17","author":"B Koullali","year":"2017","journal-title":"BMC Pregnancy Childbirth"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"P R Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"28","key":"ref21","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"P C Austin","year":"2015","journal-title":"Stat Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1198\/000313004X5824","article-title":"Model selection, confounder control, and marginal structural models: review and new applications","volume":"58","author":"M M Joffe","year":"2004","journal-title":"Am Stat"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/01621459.1987.10478441","article-title":"Model-based direct adjustment","volume":"82","author":"P R Rosenbaum","year":"1987","journal-title":"J Am Stat Assoc"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"S R Cole","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/ije\/dyu029","article-title":"Estimating predicted probabilities from logistic regression: different methods correspond to different target populations","volume":"43","author":"C J Muller","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"128.e1","DOI":"10.1016\/j.ajog.2013.10.008","article-title":"Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth","volume":"210","author":"S N Caritis","year":"2014","journal-title":"Am J Obstet Gynecol"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"398.e1","DOI":"10.1016\/j.ajog.2012.08.015","article-title":"Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation","volume":"207","author":"S N Caritis","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"02","key":"ref28","doi-asserted-by":"crossref","first-page":"233.e1","DOI":"10.1016\/j.ajog.2015.04.018","article-title":"Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate","volume":"213","author":"A L Co","year":"2015","journal-title":"Am J Obstet Gynecol"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"844.e1","DOI":"10.1016\/j.ajog.2015.08.014","article-title":"Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?","volume":"213","author":"K D Heyborne","year":"2015","journal-title":"Am J Obstet Gynecol"}],"container-title":["American Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1740010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:53:59Z","timestamp":1730811239000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1740010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":29,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,10,27]]},"published-print":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1740010","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0735-1631","1098-8785"],"issn-type":[{"type":"print","value":"0735-1631"},{"type":"electronic","value":"1098-8785"}],"subject":[],"published":{"date-parts":[[2021,12,14]]}}}